Kestra Medical Technologies (NASDAQ:KMTS) Director Conor Hanley Sells 5,694 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Director Conor Hanley sold 5,694 shares of the stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $25.25, for a total transaction of $143,773.50. Following the completion of the sale, the director directly owned 6,272 shares in the company, valued at approximately $158,368. The trade was a 47.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Down 2.1%

KMTS traded down $0.50 during midday trading on Thursday, reaching $23.57. 310,496 shares of the company’s stock were exchanged, compared to its average volume of 240,413. Kestra Medical Technologies, Ltd. has a 1-year low of $17.34 and a 1-year high of $30.00. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41. The business’s 50-day moving average price is $25.42 and its 200 day moving average price is $22.71.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The company had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. On average, analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on KMTS. Weiss Ratings downgraded Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 31st. Oppenheimer began coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating for the company. Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a report on Wednesday, July 15th. JPMorgan Chase & Co. started coverage on shares of Kestra Medical Technologies in a research report on Monday, August 10th. They issued an “overweight” rating and a $30.00 target price on the stock. Finally, BTIG Research restated a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a report on Wednesday, September 2nd. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Kestra Medical Technologies currently has a consensus rating of “Hold” and an average target price of $28.14.

Institutional Investors Weigh In On Kestra Medical Technologies

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. lifted its position in Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after acquiring an additional 474 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of Kestra Medical Technologies by 148.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after buying an additional 1,638 shares during the last quarter. Daiwa Securities Group Inc. bought a new stake in shares of Kestra Medical Technologies during the 4th quarter valued at about $72,000. Brown Brothers Harriman & Co. boosted its stake in Kestra Medical Technologies by 26.8% in the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after acquiring an additional 656 shares during the period. Finally, New York State Common Retirement Fund bought a new stake in shares of Kestra Medical Technologies in the 2nd quarter worth approximately $93,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.